KRTL Holding Group Inc. (OTC: KRTL), announced that it completed a private placement with an accredited investor for one investment unit. The unit was purchased for $125,000 and consisted of a promissory note issued by KRTL Holding Group Inc. (the “Company”) and 4,000,000 restricted shares of the Company’s common stock.
The promissory note has an investment amount of $125,000 and provides for aggregate payments to the investor of up to $250,000. The note is payable in sixteen scheduled quarterly payments of $15,625, with scheduled payments beginning after the Company first recognizes revenue from the Periko platform, as defined in the note. The Company may also satisfy scheduled payments or prepayments from other lawful sources of funds available to the Company. The note is unsecured, is not convertible into equity, and does not grant the investor voting, management, inspection, or ownership rights in the Company.
The Company expects to use the proceeds to support acquisition-related obligations, ownership-rights documentation, legal and regulatory review, and commercialization planning related to the RAYEL and PERIKO platform. The financing does not by itself constitute regulatory approval, product approval, revenue generation, or completion of all ownership-rights documentation.
The securities were issued in a private placement transaction intended to be exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The note and shares have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold absent registration or an applicable exemption from registration.
RAYEL is the Company’s TTB-approved beverage extract pathway within its documented product scope. PERIKO, is being positioned separately as a development-stage pharmaceutical/API pathway and is not being presented as an approved drug, therapeutic product, or approved API.
The Company believes that completing this financing and advancing the ownership-rights process are important supporting steps as KRTL works to organize the RAYEL and PERIKO platform for partner review, commercialization planning, and future development opportunities.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. (OTC: KRTL) operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp. The Company leverages strategic synergies across industries to pursue investments, mergers, and partnerships that deliver shareholder value. Focused on biotech, technology, and emerging market opportunities, KRTL Holding Group is committed to growth, innovation, and operational excellence.
For more information:
www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding financing use, ownership-rights alignment, acquisition-related obligations, commercialization planning, product development, partner discussions, regulatory review, revenue generation, and future business opportunities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.
Forward-looking statements include words such as “plans,” “expects,” “intends,” “may,” “could,” “believes,” “seeks,” “potential,” “pathway,” “strategy,” “commercialization,” and similar expressions. These statements are not guarantees of future performance, approval, revenue, financing, product launch, regulatory authorization, or commercial success.
Risks and uncertainties include, but are not limited to, the Company’s ability to complete ownership-rights documentation, satisfy promissory note obligations, complete definitive agreements, generate revenue from the Periko platform, qualify commercial or regulatory partners, obtain applicable approvals, complete legal and regulatory review, manage dilution, and execute its commercialization and development strategy. The Company undertakes no obligation to update or revise forward-looking statements except as required by applicable law.